Relationship between expression of ERCC1 and concurrent chemo-radiotherapy in patients with nasopharyngeal cancer
10.3760/cma.j.issn.1006-9801.2012.11.006
- VernacularTitle:DNA切除修复交叉互补基因1蛋白的表达与鼻咽癌同步放化疗疗效的关系
- Author:
Li QIN
;
Haixin HUANG
;
Haihui CHEN
;
Guisheng LI
- Publication Type:Journal Article
- Keywords:
Nose neoplasms;
Excision repair cross-complementing gene 1;
Chemo-radiotherapy
- From:
Cancer Research and Clinic
2012;(11):738-741
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the ERCC1 expression in nasopharyngeal cancer(NPC),to analyze its relationship with concurrent chemo-radiotherapy.Methods The biopsy specimens were obtained through nasopharyngeal endoscopy from patients with NPC in the Fourth Affiliated Hospital of Guangxi Medical University from January 2008 to December 2008.The ERCC1 expression in the cancer tissue was detected using MaxVision immunohistochemistry.Eight weeks after the chemo-radiotherapy,MRI was performed,The MRI results were used to assess the efficacy according to RECIST 1.1 standard,with sensitive group including complete relief (CR) and partial relief (PR) and insensitive group including stable disease(SD) and progress disease (PD).MRI was re-performed every three months with follow-up 3 years.The relationships between ERCC1 expression and concuTent chemo-radiotherapy in the short-term sensitivity and overall survival in patients with nasopharyngeal cancer were analyzed.Results 76 cases were collected.All cases were evaluable for the short-term sensitivity,and only 72 cases were evaluable for progression-free rate and overall survival (OS).In 76 short-term curative effect evaluable cases,CR was 56 cases (73.68 ％),PR was 11 cases (14.47 ％),SD was 3 cases (3.95 ％),PD was 6 cases (7.89 ％),respectively.RR (effective efficiency) was 88.16 ％ and DCR (disease control rate) was 92.1％.The positive rate of ERCC1 expression was 42.1％ (32/76),with 37.3 ％ (24/67) in the sensitive group (CR+PR) and 88.8 ％ (8/9) in the non-sensitive group (SD+PD).RR and DCR in the negative ERCC1 expression group were higher (97.7 ％,97.7 ％) than those in the positive expression group (75 ％,81.3 ％,x2 =7.119,P ＜ 0.05).Of 72 case,twelve month progression-free survival (PFS) rate was 91.7 ％ (66/72),with 95.5 ％ (39/41) in the negative ERCC1 expression group and 87.1％ (27/31) in the ERCC 1 positive group,and there was no significant difference between the 2 groups (x 2 =0,623,P =0.430).Of 72 cases,one year OS rate was 93.0 ％ (67/72),two years OS rate was 84.7 ％ (61/72),three years OS rate was 72.2 ％(52/72).Of 31 ERCC1 positive cases one year OS rate was 90.6 ％(28/31),two years OS rate was 77.4 ％ (27/31),and three years OS rate was 61.3 ％ (19/31).Of 41 ERCC1 negative eases one year OS rate was 95.5 ％(39/41),two years OS rate was 90.2 ％ (37/41),and three years OS rate was 82.9 ％ (34/41).The ERCC1 expression demonstrated significant correlation with the short-term sensitivity and OS (x2 =4.192,P =0.041).Conclusion The ERCC1 expression in NPC has negative correlation with the chemo-radiotherapy and short-term sensitivity,which may predict the chemo-radio therapy sensitivity in NPC.The ERCC1 expression in NPC has significant correlation with OS.It may predict the prognosis of NPC.
